SGLT2 inhibitor + gliclazide MR

This drug is a **combination of two oral antidiabetic agents**: an SGLT2 inhibitor and gliclazide modified release (MR). SGLT2 inhibitors work by inhibiting the sodium-glucose cotransporter 2 in the kidney, thereby reducing glucose reabsorption and increasing glucose excretion in urine. This leads to lower blood glucose levels. Gliclazide MR is a second-generation sulfonylurea that stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner and is formulated for once-daily dosing to provide prolonged efficacy and improved safety, particularly lower risk of hypoglycemia and cardiovascular neutrality. This combination is intended for the management of type 2 diabetes mellitus, especially in patients who are inadequately controlled on monotherapy. The combination enables complementary mechanisms of action: increased urinary glucose excretion (SGLT2 inhibition) and enhanced endogenous insulin release (sulfonylurea), allowing for improved glycemic control in a broad spectrum of T2D patients[1][2].

Other names

SGLT2 inhibitor and gliclazide MR combinationSGLT-2 inhibitor and gliclazide MR combinationSGLT 2 inhibitor and gliclazide MR combination